Dabigatran

( DrugBank: Dabigatran / KEGG DRUG: Dabigatran )


5 diseases
IDDisease name (Link within this page)Number of trials
51Scleroderma1
75Cushing disease1
85Idiopathic interstitial pneumonia1

51. Scleroderma


Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

75. Cushing disease


Clinical trials : 231 / Drugs : 224 - (DrugBank : 47) / Drug target genes : 63 - Drug target pathways : 145 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 768 / Drugs : 558 - (DrugBank : 126) / Drug target genes : 103 - Drug target pathways : 214 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

91. Budd-Chiari syndrome


Clinical trials : 4 / Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 12 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy


Clinical trials : 19 / Drugs : 24 - (DrugBank : 11) / Drug target genes : 6 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries